Selling to life sciences companies

Life sciences companies buy outside help when a milestone is close and the internal team can't get there alone. A trial readout, a filing, a launch. The clock drives everything.

That makes this industry one of the most rewarding for services firms that understand it. And one of the hardest for those that don't. Buyers here are scientists, regulators and operators at once. They spot a generic pitch instantly.

Who buys

The buying committee in life sciences depends on the work.

For technology and data work, the CIO or chief digital officer is often the economic buyer. In bigger companies, there's a separate head of R&D IT or clinical systems with their own budget.

For clinical operations work, the head of clinical operations or the chief medical officer has a big say. For manufacturing and supply chain, it's the head of operations or quality. For commercial work like launch planning or field force tools, it's the chief commercial officer.

And quality and regulatory leaders often have a veto. Anything touching validated systems or regulated data has to pass their review.

The pressures they face

Timelines are the first. Every month a drug spends in development costs money and delays revenue. Companies push hard to speed up trials, submissions and launches.

Regulation is the next. Systems that support clinical trials, manufacturing and safety reporting have to meet strict validation rules. Changes take longer and cost more than in other industries.

Data is everywhere and scattered. Clinical, manufacturing, commercial and real-world data often live in separate systems. Bringing them together is hard work, and it pays.

And funding shapes everything for smaller companies. A biotech that just raised money has a runway and a plan. A biotech that's running low is cutting.

The signals that matter most here

Funding and deals are among the strongest signals in this industry. A biotech that closes a round usually has a specific plan for the money, often a trial or a manufacturing scale-up. A pharma company that licenses or acquires an asset has integration and launch work ahead.

Milestones in filings are next. Public companies describe upcoming trial readouts, submissions and launches in their 10-Ks and earnings releases. Each one implies a burst of work.

A new leader matters a lot. A new head of clinical operations or a new CIO comes in with a mandate and a short window.

Hiring for the problem is clear here too. A company posting roles for clinical data managers, validation engineers or launch analysts is telling you where it's stretched.

An example opener

Say a mid-size biotech just closed a funding round and its press release said the money would take its lead program into a late-stage trial. The head of clinical operations is your likely champion.

Saw the round will carry your lead program into a late-stage trial. Going from a few sites to dozens in a short window, my guess is the data management and site monitoring setup that worked earlier won't hold at the new scale. Is that the worry, or is the harder part somewhere else in the plan?

It names a real event. It ties it to the person's job. It guesses at a problem they'll recognize. And it's easy to correct.

What to avoid

Don't pretend to know the science if you don't. Life sciences buyers respect firms that know their lane. If you're a data firm, talk about data. Leave the biology to them.

Don't ignore validation. If your work touches regulated systems, show early that you understand the rules. A firm that treats validation as an afterthought won't get past the quality team.

And don't overlook smaller companies. Mid-size biotechs often need outside help more than big pharma does, since they're building capabilities fast with lean teams.

Where to start

Pick a segment you know. Clinical data, manufacturing systems, commercial launch, whatever your firm does best. Watch the companies in that segment for funding, milestones, new leaders and hiring.

When a few of those land at one company in the same stretch, reach out to the committee. The guide to buying signals explains how to weigh them. In life sciences, a milestone date plus fresh funding is about as clear as an opening gets.